Adicet Bio Inc (ACET)
Adicet Bio, Inc. is a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. Its lead candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy engineered with a CAR that targets CD20 and is being studied for potential use in autoimmune diseases. The company is also advancing ADI-212, a gene-edited, armored clinical candidate designed to target prostate-specific membrane antigen. Founded in 2014, Adicet Bio is based in Boston, Massachusetts. The company’s common stock is listed on NASDAQ under the ticker ACET.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ACET
|
$11.94
|
48.5% Upside
|
Undervalued
|
$34.83
|
333.3% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-0.8x
|
0.6x
|
—
|
82.853 M
|
-38.845 M
|
14.4%
|
70.7%
|
-3.8
|
—
|
84.2%
|
